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1. Introduction
Interest has increased in the use of arterial conduits for CABG significantly in most major
cardiac surgery centers around the world, because the number of patients receiving arterial
grafts and our knowledge about the biologic characteristics of arterial grafts have increased.
In addition, more advanced clinical protocols for the use of grafts have been developed and
midterm results with alternative arterial grafts are encouraging.
The internal mammary artery (IMA) has been shown to have greater long-term patency for
coronary artery bypass grafting when compared with the saphenous vein graft. Because of the
superior long-term results of the IMA, other arterial grafts which have recently been advocated
include the radial artery (RA), the gastroepiploic artery (GEA), the inferior epigastric artery
(IEA), the splenic artery, the subscapular artery, the inferior mesenteric artery, the descending
branch of lateral femoral circumflex artery, the intercostal artery and the ulnar artery. One of
the various manifestations clinically observed among these arterial grafts is a different
tendency to develop spasm during surgical dissection and during the perioperative period
which could be the cause of perioperative morbidity and mortalitiy [1-8]. For example, there
are reports of vasoactive drugs altering IMA graft flow [3,4]. Moreover, there is accumulating
evidence that blood flow in arterial grafts is insufficient in some circumstances [6,7]. Many
vasoconstrictors (spasmogens) may cause arterial grafts spasm. Accordingly, antispastic
therapy is important in the development of arterial grafts and the nature of constrictor
substances that cause arterial graft spasm needs to be determined. In recent years, the problem
of graft spasm has become more frequent with the increasing use of new arterial grafts.
Therefore, it is essential for surgeons to understand the causes of vascular graft spasm, to
improve patency rates and to use the optimal vasodilator in the most appropriate way to
counteract vasospasm.
© 2013 Yildiz et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Surgeons have studied graft pharmacology by measuring the effects of vasodilators on blood
flow through arterial grafts before they were attached to the heart [9]. Pharmacologists have
also joined the study of graft pharmacology by evaluating endothelial and smooth muscle
function of bypass grafts using their standard in vitro method, the isolated vessel ring
preparation in the organ bath. However, results from these in vitro studies need to be carefully
extrapolated to the clinical situations, where the conditions of the arterial grafts are compli‐
cated. Even so, the organ bath method can provide very useful information about the effects
of vasoactive substances in the arterial grafts.
Several vasodilators have been tested and various antispastic methods have been suggested
to prevent graft spasm; including papaverine, phenoxybenzamine, calcium antagonists and
nitrates etc. Choice of a pharmacological agent to overcome the vasospasm encountered in the
arterial grafts must be on the basis of pharmacological studies. Accordingly, current state of
knowledge based on experiments to study the pharmacological effect of a number of vaso‐
constrictor and vasodilator substances and the practical application of this knowledge can be
outlined as following sections:
2. In Vitro pharmacology of blood vessels
Pharmacology of isolated blood vessel allows the researcher to investigate the mechanisms of
effect of spasmogens or vasodilatory substances. Most studies use the isolated vessel ring
preparation in the organ bath, studying removed segments from the grafts during surgery.
This technique only requires basic pharmacological equipment, i.e. isolated organ baths,
transducers, recorder system etc. An important advantage of this method is that the vessel
segment is studied in the organ bath and concentration-response curves for each vasoactive
substances to be obtained under controlled conditions without extrinsic neural factors,
circulating hormones interacting, blood flow or shear stress. Therefore, dose and response
relationships to drugs, either vasoconstrictor or vasodilator substances, can be assessed more
readily and accurately than is possible than in vivo experiments. This methodology also
enabled agents to be compared with each other, and combinations of vasoactive drugs to be
tested [10,11-13]. In vitro measurement of response of vascular preparations may help to
researcher to predict what can happen, not what does actually happen in integrative and
complicated in vivo conditions. However, isolated organ bath methods cannot identify the
actual cause of in vivo spasm. The next challenge is to determine in the body what combination
of factors, i.e. extrinsic neural factors, circulating hormones interacting, blood flow or shear
stress, influencing passive distension from arterial wall are present the vessel with spasm.
Isolated organ bath technique is a standard research approach which requires basic pharma‐
cological equipment (Figure 1). Segments of human arteries obtained from patients undergo‐
ing CABG surgery are placed in oxygenated physiological solution, i.e. Krebs-Henseleit
solution etc., at room temperature and transferred immediately to the laboratory. The arteries
are dissected from adhering fat and connective tissue then cut into 3-4 mm length rings. The
strips are mounted in an organ bath, containing physiological solution, on a L-shaped brace
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for tension measurement along the former circumferential axis. The solution is gassed with %
95 O2 and % 5 CO2 at 37 ºC. Changes in arterial tensions are recorded isometrically by a force-
displacement transducer by using a recording system, preferably a computer software. The
segments are allowed to equilibrate under final resting force of 1-2 g for at least 1 to 1.5 h and
they were washed every 10-20 minutes. After the equilibration period, arterial strips were
challenged with a vasoconstrictor, i.e. phenylephrine, prostaglandin F2α or potassium chloride
(KCl) to test the viability of the vessel. After an additonal 30 min of equilibration period with
repeated washing every 10 min, the tissues are challenged with increasing cumulative
concentrations of the vasoconstrictor substance to be tested and responses are recorded.
Figure 1. A schematic diagram of a human arterial ring preparation in an organ bath.
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Each cumulative concentration is applied after the relaxation to previous concentration
reached to a plateau. Vasoconstrictor substance -evoked responses are usually expressed as
percentage of the maximum response in each corresponding tissue. Vasodilator agents are
studied by establishing concentration-relaxation curves after precontracting the segments with
a vasoconstrictor, i.e. phenylephrine, prostaglandin F2α or potassium chloride (KCl). The
relaxation is usually expressed as a percentage of the precontracting force. Potency, ie,
sensitivity of the vessel to a drug is calculated as EC50 values (the concentrations of vasocon‐
strictor required to produce 50 % of the calculated maximum response). EC50 value is used to
determine pEC50 value (negative log10 of the EC50 value). This value can differ considerably
with the nature of the agent used for precontraction of the vessel and the amount of contraction
that a particular concentration of vasoconstrictor substance will develop. The degree of
relaxant effect of a dilator on a vessel precontracted by a particular vasoconstrictor agent,
namely functional antagonism, is reflected by pEC50 value. Another important value is the
maximal efficacy (Emax) which reflects the range of maximal response to the drug at high
concentration.
A special method that measures the individual length-tension relationship curve for each
vessel segment, cut to a precise length, has been developed [10]. This method, called as
normalization technique, sets passive distension of the vessel segment to correspond with that
caused transmural pressure experienced in vivo. The principal is to establish individual length-
tension exponential curves for each vessel by relating the isometric tension, obtained from
strain gauge transducers, with the corresponding diameter. This technique has been conti‐
nously used by several researchers for studying CABG pharmacology [10,14-16].
2.1. Vasoconstrictor and vasodilator agents
Exogenous and endogenous vasoconstrictors  are  particularly  important  for  vasoconstric‐
tion and its extreme form—vasospasm (Figure 2). Table 1 lists vasoconstrictor substances
that are generally considered spasmogens for blood vessels and the receptors located on
the cellular  membrane of  vascular  smooth muscle,  and of  endothelium, which mediates
vasodilatation.  Most  of  these  vasoconstrictor  substances  contract  blood  vessels  through
receptor-mediated  mechanisms,  i.e.  internally  secreted  epinephrine  and  norepinephrine
cause  blood  vessels  to  contract  by  stimulating  α-adrenergic  receptors  on  the  vascular
smooth muscle.  Consequently,  a  selective α -receptor antagonist  will  be highly effective
because the site of interaction is same. The contraction caused by epinephrine and nore‐
pinephrine is partly caused by depolarization of the tissue through voltage-operated cal‐
cium  (Ca2+)  channels  (VOCC)  and  partly  caused  by  calcium  release  from  intracellular
sources.  Thus,  this  mechanism would  be  more  resistant  to  functional  antagonist  nifedi‐
pine. On the other hand, increased extracellular K+ depolarizes smooth muscle membrane
by closing of the hyperpolarizing K+  channels.  This effect allows VOCC to open and in‐
tracellular [Ca2+  ]  to rise, resulting in smooth muscle contraction. Therefore, a VOCC an‐
tagonist such as nifedipine would readily relax a tissue precontracted by potassium (K+).
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Endothelin ETA, ETB ETB
α-Adrenoceptor agonists






TxA2 * TP TP (?)**
Prostanoids
TxA2 * TP TP (?)**
PGF2α FP FP (?)**
Substances released from
mast cells and basophils




Angiotensin II AII AII
Vasopressin (ADH) V1**** …
Depolarizing agent
Potassium …
* TxA2 is also considered as one of the endothelium-derived contracting factors; it is also derived from platelets.
** TP and FP receptors in endothelial cells to be clarified.
*** Dopamine also affects α1 and α2 receptors, exist in cardiac and bronchial cells respectively, it causes vasoconstriction
at high dose.
**** Mainly effective in renal medulla, it also enhances sympathetic constriction,
EDCFs = Endothelium-derived contracting factors, ADH = antidiuretic hormone.
Table 1. Vasoconstrictors and their Receptors Involved in Vascular Smooth Muscle; Vasodilators in which Mediate
Relaxation via Endothelium.
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As stated above, vasodilator agents are usually studied by precontracting the vessel. The level
of precontraction force should be chosen in the range of 60% to 80% of the maximum contrac‐
tion of that agent. The precontractile tone should reach to a plateau and remain stable during
the experimental period. The precontraction may dissipate in a time-dependent manner. This
may lead researcher to ascribe decreased tone due to added drug instead of spontenaous
relaxation. Therefore, a parallel time control is necessary to show that the precontraction is
stable [11,17,18].
2.2. Influence of endothelial functions on contractility of arterial grafts
It  has been well  known that vascular endothelium plays an important role in maintain‐
ing vascular tone. Endothelium derives a number of vasoconstrictor as well as vasodila‐
tor substances. Vascular tone is maintained on the balance between vasoconstriction and
vasodilatation  caused  by  these  substances.  Endothelial  cell  produces  endothelium-  de‐
rived  contracting  factors  (EDCFs)  such  as  endothelin  (ET)  and  thromboxane  A2  (TxA2)
that cause an increase in the intracellular calcium concentration and mediate contraction
of the smooth muscle.  Endothelium-dependent relaxation is  known to be the effect  of  a
variety  of  different  endothelium-derived  relaxing  factors  (EDRFs).  These  are  endotheli‐
um-derived nitric  oxide  (NO)  [19,20],  prostacyclin  (PGI2)  [21],  and endothelium-derived
hyperpolarizing  factor  (EDHF)  [22-25].  These  relaxing  factors  induce  vasodilatation
through different mechanisms by reducing the intracellular calcium concentration in the
smooth muscle cell and cause relaxation. Spontaneous (basal) release of EDRF (NO) also
depresses the contraction to some extent. As in other vessels, endothelium plays a modu‐
latory role in contractility in CABGs [26]. Studies on endothelial function of CABGs have
indicated that arterial endothelium has more ability to produce NO than venous endothe‐
lium (11-13, 26). EDHF also plays a role in arterial grafts [17].
Endothelin, prostanoids (TxA2 and PGF2α) and α1-adrenoceptor agonists are the most potent
vasoconstrictors and they strongly contract arterial grafts even when endothelium is intact.
On the other hand, some vasoconstrictors, i.e. serotonin (Serotonin (5-hydroxytryptamine, 5-
HT)), have been demonstrated as being vasorelaxant agents through the mechanism of EDRF
(NO). They induce contraction by their direct contractile effect on smooth muscle, and
vasodilatation, induced by EDRF (NO) or EDRFs release due to its stimulation to endothelium.
Therefore, these vasoconstrictors do not strongly contract the vessels in endothelium-intact
blood vessels. However, when endothelium is damaged or denuded, they evoke a strong
contraction.
3. Pharmacology of internal mammary artery
Vasoconstriction may be evoked by various stimuli such as vasoconstrictor substances, nerve
stimulation and mechanical trauma. Clinically, although all arterial grafts may develop
vasospasm, it develops less frequently in IMA and IEA than in GEA and RA [7,27]. Compa‐
rative functional studies have demonstrated that there are differences in arterial grafts with
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regard to contractility and endothelial function. These differences, together with histological
and anatomical diversity, may account for possible differences in the perioperative spasm.
The contractility of IMA to vasoconstrictors has been studied extensively [10,13]. TxA2 is one
of the several EDCFs, but it is also derived from platelets. Endothelin is also considered as one
of the EDCFs. These two substances are two of the most potent vasoconstrictors known and
they are very potent in IMA as well. Elevated plasma concentrations of ET [28] or TXA2 [29]
have been found during cardiopulmonary bypass. Therefore,.these vasoconstrictors are prime
candidates as spasmogens for arterial grafts during CABG surgery.
Some receptors on the smooth muscle of IMA have been characterized. For example, IMA is
an α1-adrenoceptor-dominant artery with little α2- or β -function [30,31]. Other receptors
functionally demonstrated in IMA are ETA, ETB [32], 5-HT [33], angiotensin [34],TP (throm‐
boxane-prostanoid) [35], vasopressin V1 receptors [36,37], and vasoactive intestinal peptide
[38] receptors. Dopaminergic receptors have also been demonstrated in the IMA [39]. The
agonists for these receptors may also be spasmogenic agents for the IMA.
As  stated  above,  some  vasoconstrictors  have  been  demonstrated  as  being  vasorelaxant
agents.  5-HT is an example of this type of vasoconstrictors and it  directly contracts vas‐
cular smooth muscle through 5-HT2  receptors [40] and relaxes blood vessels through en‐
dothelial  NO  release,  mediated  by  5-HT1D  receptors,  [41]  located  in  the  endothelium.
When endothelium is  lost,  perhaps  also  when it  is  damaged,  platelets  aggregate  in  the
area  where  endothelium  is  denuded  and  release  substances  such  as  5-  HT  (also  TxA2)
that  strongly  contract  smooth  muscle.  Accordingly,  studies  have  shown 5-HT does  not
strongly contract IMA with intact endothelium [13,42].  However,  its contracting effect is
unmasked when endothelium is denuded [13,42].
The endothelium-dependent relaxation exists in IMA [43]. It has also been demonstrated
that vascular endothelial growth factor may induce endothelium-dependent relaxation in
the  human IMA [44];  the  relaxation has  recently  been demonstrated to  be  mediated by
both NO and PGI2 [45]. Further, physiological substances such as CRF induce both endo‐
thelium-dependent  and  -independent  relaxation  in  the  human  IMA  [46].  IMA  releases
both NO and EDHF [47]. Recent studies have demonstrated that the endothelium of the
IMA releases more NO than the RA at both basal and stimulated levels [47]. Further, the
IMA has a greater hyperpolarizing effect on bradykinin-stimulated release of EDHF than
the RA does [47].
In addition, receptors, for common stimuli of EDRF such as acetylcholine, bradykinin, and
substance P are present in the endothelium of arterial grafts [15,48,49]. The vascular endothelial
growth factor (VEGF)-induced, endothelium- dependent relaxation, mediated by both NO and
prostacyclin in the IMA, has been shown mainly through the KDR (kinase insert domain)
receptors, rather than Flt-1 (fms-like thyrosine kinase-1) receptors [45]. Most recently, corti‐
cortropin-releasing factor (CRF) receptors CRF1, CRF2α, and CRF2β have been shown to be
present in the IMA [45]. The CRF urocortin- induced endothelium-dependent relaxation in the
IMA is likely through CRF receptors allocated in the endothelium of the IMA [50].
Pharmacology of Arterial Grafts for Coronary Artery Bypass Surgery
http://dx.doi.org/10.5772/54723
257
3.1. Spasm of internal mammary artery
Compared to saphenous grafts, IMA is more resistant to ischaemic changes due to high content
of elastin with a low metabolic rate. Occasionally, there is severe contraction (spasm), which
may be visible or be inferred by minimal free flow. Spasm of IMA can cause inadequate blood
flow, which may be detrimental during periods of increased nutritional demand such as
weaning from cardiopulmonary bypass [51] or postoperative hypovolemia [52]. In addition,
IMAs with poor perioperative flow rates are more likely to occlude [53]. Severe spasm may
lead to graft malfunction and even mortality [11,54]. It is essential to to determine whether the
IMA should be discarded or alternatively relegated to graft a minor vessel. Thus, a dilator
drug, preferably a fast-acting one suitable for intraluminal injection, should be used for
maximal pharmacologic dilation of the IMA, which allows the surgeon to evaluate the flow-
carrying capacity of the IMA and provides a relaxed, dilated distal vessel that facilitates a
precise anastomosis. Vasodilation of the IMA pedicle during CABG surgery may also unmask
small bleeding points, improve hemostasis and facilitate placement of anastomotic sutures [9].
Vasoconstriction (or spasm) of IMA may be caused by multiple mechanisms. In addition,
vasodilators relax vascular smooth muscle through a specific mechanism or mechanisms.
Several vasodilators have been suggested to prevent graft spasm; including papaverine,
phenoxybenzamine, calcium antagonists and nitrates. However, there is no “perfect” vasodi‐
lator which is effective for every situation.
Figure 2. Endothelium-derived relaxing factor (EDRF) is produced and released by the endothelium to promote
smooth muscle relaxation. NO, nitric oxide; AII, angiotensin II receptors; ACh, acetylcholine; EDHF, endothelium-de‐
rived hyperpolarizing factor; ET, endothelin; FP, PGF2α receptors; H (H2), histamine receptors; His, histamine; K, potassi‐
um; M (M2), muscarinic receptors; NE, norepinephrine; PE, phenylephrine; PGI2, prostacyclin; 5-HT, 5-
hydroxytryptamine (serotonin); TP, thromboxane-prostanoid receptors; VOC, voltage operated channels; α, adrenergic
receptors
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3.2. Effect of vasodilator substances on IMA
To promote dilation of the IMA, some vasodilating substances have been applied to the outside
of the pedicle [55-58] or injected intraluminally with or without hydrostatic dilation
[9,55,56,58,59]. The vasodilator substances available are as follows:
Papaverine
The traditional topical  vasodilator papaverine was first  recommended by George Green,
the  pioneer  IMA surgeon,  in  early  days  of  IMA grafting  to  overcome spasm [60].  It  is
still widely used due to its satisfactory vasorelaxant effect in arterial grafts [61,62]. Papa‐
verine is  a non specific  vasodilator substance which relaxes vessels via multiple mecha‐
nisms  such  as  inhibition  of  phosphodiesterase  [63],  which  increases  cyclic  guanosine
monophosphate (cGMP) level in smooth muscle cells, decreasing calcium influx [64,65] or
inhibition of  release  of  intracellularly  stored calcium [66].  Although hydrostatic  dilation
with  papaverine  dissolved  in  saline  solution  provides  good  dilation  at  high  concentra‐
tions, it carries a potential risk of mechanical damage to the media and intima caused by
cannulation and overstretching and by chemical damage as a result of the acidity of the
solution  [67-70].  The  problem  of  acidity  of  papaverine  solutions  may  be  overcome  by
mixing the solutions with blood or albumin before its use [71]. However, the pharmaco‐
logical action is uncertain in such a mixture. Additionally, papaverine has a slower onset
of  the  vasodilating  effect  when  compared  to  other  vasodilators  such  as  nitroglycerin
(NTG)  and  verapamil  [10,62,72].  However,  once  its  effect  reaches  a  plateau,  it  is  sus‐
tained [10,62,72].  Papaverine  hydrochloride  is  relatively  unstable  in  non-acidic  solutions
and a  white  precipitate  is  sometimes formed when papaverine is  added to  the  plasma‐
lyte solution (pH approximately 7.4)  [73].  In light  of  these points,  papaverine is  still  an
effective vasodilator for IMA. Its topical spray on the adventitia of the IMA may be effec‐
tive but it is not recommended for systemic use.
Nitrovasodilators
Nitrovasodilators (organic nitrates), NTG, glyceryl trinitrate (GTN) and sodium nitroprusside
(SNP), are a diverse group of pharmacological agents that produce vascular relaxation by
releasing NO, which activates guanylate cyclase, resulting in an accumulation of cyclic GMP
in the smooth muscle cell. This in turn reduces intracellular calcium concentrations and leads
to vasodilatation. These drugs are effective against a range of constrictor stimuli and they are
widely used in CABG patients. Nitrovasodilators have been shown to be potent vasodilators
in the human IMA [55,61,74-79]. It has been demonstrated that NTG is compares favorably
with diltiazem in the prevention of IMA spasm [80] and it is effective for either topical,
intraluminal, or systemic use [78,81,82]. Although, nitrates are slightly more effective in
blocking receptor operated channels, they are effective in treating established vascular spasm,
regardless of the nature of contraction, i.e., either receptor mediated (TxA2 receptors, α-
adrenoceptors, or ET receptors) or depolarizing agent (K+)- mediated contraction [10,54].
However, rapid tolerance (tachyphylaxis) of vessels develops to nitrovasodilators. Therefore,
they are less potent in the prevention of vasospasm [54,74,75,83]. NTG is more potent in its
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vasorelaxing effect when it is compared to SNP. However, SNP is more effective in inhibition
ANGII and α-adrenoceptor-mediated contraction in the IMA [34].
Phosphodiesterase inhibitors
Phosphodiesterases (PDE) are a diverse family of enzymes that hydrolyse cyclic nucleotides
and thus play a key role in regulating intracellular levels of the second messengers cyclic
adenosine monophosphate (cAMP) and cGMP which modulate vascular smooth muscle tone.
Concentrations of cAMP and cGMP are controlled through synthesis by cyclases and through
hydrolysis by PDEs. Non-selective PDE inhibitors including papaverine have been injected
routinely by surgeons, in and around the artery to prevent IMA spasm, but papaverine is not
administered systemically. The discovery of eleven types of PDEs [84,85] provides an impetus
for the development of isoenzyme selective inhibitors for the treatment of various diseases.
Inamirinone (previously called amrirone) and milrinone are bipyridine compounds that
inhibit phosphodiesterase (PDE) III, a form found in cardiac and smooth muscle. Therefore,
they increase myocardial contractility and vasodilation, and they are called as ‘inodilators’.
These drugs are useful in postoperative management of patients who undergo open heart
surgery, particularly in patients who present ventricular dysfunction and receive arterial grafts
for coronary artery bypass surgery. Favorable effects of inamrinone on the IMA [76,86-88] have
been reported. In addition, it has been demonstrated that inamrinone has a greater than
additive vasodilatory effect when used in combination with NTG [76]. It was also demon‐
strated that systemically administered milrinone and nitroglycerin dilate the IMA after
cardiopulmonary bypass [82]. Levosimendan is a new agent developed for the treatment of
acute and decompensated heart failure. It exerts potent positive inotropic action and peripheral
vasodilatory effects. The mechanism of vasodilation by levosimendan may involve reduction
of Ca2+ sensitivity of contractile proteins in vascular smooth muscle, the lowering of intracel‐
lular free Ca2+, the potential inhibition of PDE III, and an opening of K+ channels [89,90]. We
have recently shown that levosimendan effectively and directly decreases the tone of IMA [91].
Therefore, levosimendan may be a cardiovascular protective agent by its relaxing action on
IMA.
Calcium antagonists
It has been known since the late 1800s that calcium influx was necessary for he contraction of
smooth and cardiac muscle. The discovery of calcium channel in smooth and cardiac muscle
was followed by the finding of several different types calcium channels including VOCC (L,
T, N and P types) and receptor -operated calcium channels, (ROCC). The discovery of these
channels made possible the development of clinically useful new generation calcium antago‐
nists (calcium channel blockers). These drugs are consist of three chemically divergent groups:
Dihydropyridine (nifedipine, etc.), phenylalkylamines (verapamil, etc.), and benzothiazepines
(diltiazem, etc.). Important differences in vascular selectivity exist among the calcium antag‐
onists. In general, nifedipin is the most potent. In addidion, verapamil is more potent than
diltiazem. It has been demonstrated that nifedipine is more potent than diltiazem with regard
to the vasorelaxant effect in the human IMA [54].
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The degree of vasodilatory effect of calcium antagonists is dependent on the nature of
contraction. Calcium antagonists are less effective in blocking receptor-operated than voltage-
operated calcium channels. For example, increased extracellular K+ depolarizes smooth muscle
membrane by closing of the hyperpolarizing K+ channels. This effect allows VOCC to open
and intracellular [Ca2+] to rise, resulting in smooth muscle contraction. Therefore, a VOCC
antagonist such as nifedipine would readily relax a tissue precontracted by K+. On the other
hand, the contraction caused by receptor agonists is partly caused by calcium influx and partly
caused by calcium release from intracellular sources. Consequently, calcium antagonists are
weak in either preventing or treating TxA2, α-adrenoceptor, or VP1 receptor-mediated
contraction, in comparison to K+-mediated contraction [54,74,92,93].
Potassium (K+) channel openers
Drugs that open potassium channels (potassium channel openers, KCOs) can exert antivaso‐
constrictor and vasorelaxant actions, that is, they reduce or prevent cellular response ro
excitatory stimuli, repolarize or hyperpolarize the cell membrane, overcome a contraction once
it has developed, and strengten the resting state of the vessel. KCOs are considered to comprise
a heterogeneous group of organic compounds [94]. These are apricalim, bimakalim, celikalim,
cromakalim, levokromakalim, diazoxide, L-27,152, P 1075, minoxidil sulphate, pinacidil, and
nicorandil. KCOs act by stimulating ion flux through a distinct class of potassium channels
which are inhibited by intracellular adenosine triphosphate (ATP) and activated by intracel‐
lular nucleoside diphosphates. They restrain the opening probability of voltage-dependent L-
and T-type calcium-channels and decrease agonist-induced Ca2+ release from intracellular
sources through inhibition of inositol trisphosphate (IP3) formation, and lower the efficiency
of calcium as an activator of contractile proteins [95]. Additionally, they may accelerate
clearance of intracellular free calcium via the Na+/Ca2+ exchange pathway [95]. The functional
outcome of these effects is to reduce the membrane excitability and to drive vascular myocytes
into a relaxed state. Particularly, vascular smooth muscle is sensitive to KCOs [96-99]. In view
of these points, KCOs are of great value as therapeutic agents [98,99,] and aprikalim [100,102]
have been studied in the human IMA and found to be potent vasodilators in a number of
receptor-mediated contractions. Therefore, this group of drugs may become clinically useful
antispastic agents by their relaxing action on IMA.
α-Adrenoceptor antagonists
IMA is an α1-adrenoceptor-dominant artery with little α2- or β -function [30,31,103]. Theoret‐
ically, a selective α -receptor antagonist may be a highly effective antispastic agent because the
site of interaction is same. Herewith, the use of α-adrenoceptor antagonists such as phenoxy‐
benzamine as an antispastic agent has a rationale. However, the nature of vasoconstriction is
complex and may involve many other vasoconstrictors (Table 1). It has been demonstrated
that, α- adrenoceptor antagonists are not effective in reversing the contraction evoked by other
vasoconstrictors such as vasopressin, angiotensin II, endothelin-1, and KCl [104]. From
pharmacological point of view, use of phenoxybenzamine is inappropriate as the sole anti‐
spastic agent in the arterial grafts. Moreover, a novel α1-adrenergic receptor blocking substance
with calcium antagonist with activity, AJ-2615, has been studied with regard to inhibition of
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vasoconstriction in the IMA [44]. Further studies on this kind of substances may provide
development of new antispastic protocols.
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) has been studied in the human IMA and found to
be a potent vasodilator through KDR receptors and NO -and PGI2 -mediated mechanisms
[44,45]. However, VEGF has potent hypotensive effect due to systemic vasodilaton [44,45].
Therefore, the use of VEGF as a vasorelaxant agent may not be the primary consideration for
antispastic therapy in arterial grafts.
β-Adrenoceptor agonists: Dopamine and dobutamine
Albeit at least three distinct beta-adrenoceptors exist in IMA [105], β -receptor function is weak
[31]. Consequently, it has been demonsted that use of β -adrenoceptor agonists is unlikely relax
the IMA significantly [106]. Same study also indicated that beta-receptor agonist dobutamine
exerts weak vasodilator effect in IMA. Dopamine-induced responses are complex and dose-
dependent, inasmuch as the complexity of interaction between dopamine and dopamine
receptors as well as α1-adrenoceptors [107]. In IMA, dopamine induced a vasorelaxation on
the norepinephrine contraction only at higher concentrations [107]. Similar to VEGF, the use
of dopamine and dobutamine may not be the primary consideration for antispastic therapy.
On the other hand, vasodilator effect of β-adrenoceptor agonists in IMA at high concentrations
should be kept in mind when these agents are used primarily as inotropic agents.
TxA2 antagonists
TxA2  is one of the the most potent vasoconstrictors known and it is very potent in IMA
as well [10,13]. Inasmuch as its importance in thrombosis together with its elevated plas‐
ma concentrations during cardiopulmonary bypass, specific TxA2 antagonists may be use‐
ful in the antispastic therapy of IMA. Accordingly, specific TxA2 antagonist GR30191 is a
potent vasodilator for TxA2-mediated contraction in IMA [86]. However, to date, no clini‐
cal data are available.
5-HT receptor antagonists
Studies  on  human  IMA  have  shown  that  5-HT  directly  contracts  IMA  through  5-HT1D
and 5-HT2  receptors  [33,108-110].  In  IMA,  5-HT receptor  mediated  contractions  are  un‐
masked  when  endothelium  is  denuded  [13,42].  Additionally,  studies  have  shown  5-HT
may interact synergistically with other vasoconstrictor substances, such as TxA2  released
from platelets during thrombus formation, and 5-HT receptor mediated contractions may
be unmasked or amplified [33,108-110]. 5-HT2A receptor antagonist ketanserin has antihy‐
pertensive properties  and it’s  recently used to reduce the severity and frequency of  the
vasospasm  in  Raynaud’s  phenomenon  [111].  Therefore,  it  may  have  potential  to  over‐
come IMA spasm when it’s applied topically.
Testosterone
Testosterone  may  exert  vasorelaxant  effects  on  several  vascular  tissues  [112-119].  We
have studied effects  of  testosterone in  the human IMA and found that  vasorelaxant  re‐
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sponse  to  testosterone  may  occur  in  via  large-conductance  Ca2+-activated  K+  channel-
opening  action  [112].  Clinical  studies  of  testosterone  therapy  in  male  patients  with
coronary  artery  disease  raised  promising  results.  Therefore,  the  use  of  testosterone,  i.e.
direct topical administration on adventitia, as a vasorelaxant agent may be considered for
antispastic therapy in arterial grafts.
Iloprost and botilinum toxin
It has been demonstrated that botilinum toxin may prevent arterial spasm in vitro [120].
Iloprost, a PGI2 analogue, may be considered as an alternative antispastic agent in arteri‐
al grafts [121].
4. Pharmacology of other arterial grafts
4.1. Radial artery
The use of the RA as a graft for coronary revascularization was already introduced in the 1970s,
but shortly thereafter it was abandoned due to high incidence of vasospasm and comparatively
poorer short-term and long-term patency rates than IMA [27,122-124]. This was partly due to
the inability to recognize RA spasm, but it was also due to lack of proper pharmacological tools
to prevent this. It was later noted that radial grafts were indeed patent in patients long after
their surgery. Thereafter, the RA was reassessed and its role as an alternative arterial graft was
re-established.
Because of the dual blood supply to the hand, RA occlusion is not associated with major clinical
sequelae but prevention is important. RA spasm rarely leads to serious vascular complications
but can cause patient discomfort and can result in prolonging or failure of the procedure.
Several studies now suggest that the vasospastic tendency of RA grafts has been countered in
the operating room (immediately after harvest) by treating the artery with papaverine or
milrinone, or both, and placing it in a bath of heparinized saline containing NTG or a combi‐
nation of NTG and a calcium channel blocker to prevent spasms. Similarly, protection from
immediate postoperative and postdischarge vasospasm is sought through the use of intrave‐
nous or oral combinations of the aforementioned vasodilator drugs. However, clinical studies
indicate that such vasodilatory precautions do not provide the expected protection from
postoperative vasospasm of RA grafts. Although the patency rate of RA is debatable, mid-term
and long-term patency rates may reach 90% and greater, that makes the RA a valuable addition
in arterial grafting [125,126].
RA has less active endothelium compared to IMA and is stronger receptor-mediated contrac‐
tions can be evoked in the RA than in the IMA [49,127], which presumably predisposes it to
higher incidences of spasm. Additionally, it was previously reported that RA grafts are more
sensitive to TxA2 [13]. Furthermore, it has been reported that IMAs produce substantial
amounts of both PGI2 and TxA2 [128]; nonetheless, the TxA2 to PGI2 ratio was significantly
higher in the RA than in the IMA. Because PGI2 antagonizes the actions of TxA2, the higher
TxA2 to PGI2 ratio implies that TxA2 would exert greater effects in the RA. Contraction to KCl
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in the RA is stronger than in the IMA or the GEA [16]. The RA is more reactive than the IMA
to angiotensin II and ET-1, but the endothelial function of the RA is similar to the IMA [49].
Pharmacological and non-pharmacological strategies have been evaluated to prevent RA
occlusion and RA spasm. A number of pharmacological 'cocktails' have been successfully
tested but there is currently no agreement on the optimal combination of agents. RA studied
in vitro was found to relax fully either to GV solution or to papaverine, but the relaxation to
GV solution was more rapid in onset and of longer duration than for papaverine [62]. GV (GTN
+Verapamil) solution has been found to be satisfactory when is used on the RA to dilate it
during harvesting and preparation and it [11,129]. It can be argued that GV solution represents
the optimum agent for RA spasm when used in the perioperative period [129]. It has been
suggested that a 'cocktail' of agents may be given to counteract RA spasm before transradial
coronary angiography or angioplasty [130]. A combination of heparin, NTG and verapamil
seems to be associated with the best preventive outcome [130].
4.2. Gastroepiploic artery
Excellent long-term angiographic results have been reported with GEA [131], but its progres‐
sive loss of caliber with mobilization and its greater tendency for vasospasm compared with
other arterial conduits both in in vitro testing [13] and in clinical practice [7] has limited its
widespread use.
Spasm of the GEA is a well-described clinical phenomenon [7] Some studies have suggested
that the GEA and the IMA have similar response to NE, phenylephrine, and 5-HT [132,133],
and that the IMA is more reactive to the TXA2 mimetic, U46619. On the other hand, Dignan
and associates [15] have found that the GEA has a stronger contractility than the IMA and
more reactive to K+, NE, and 5-HT. He and Yang [13,134] compared the contractility of the
GEA, the IMA, and the IEA and found that among arterial grafts the GEA has the highest
contractility. Variation of techniques used in the studies may account for diverse results from
different groups. Therefore, the above mentioned vasoconstrictors may be the spasmogenic
agents for the GEA [15]. Additionally, relaxation of the GEA to SNP [15] or to endothelium-
dependent vasodilators [134,135] appears to be similar to the IMA.
Several vasodiators have been studied to counteract GEA spasm [81,136]. It has been demon‐
strated that papaverine, when given externally on the perivascular fat of the GEA, prevents
GEA spasm for up to 2 hr [136]. In contrast, intraluminally applied papaverine does not show
graft protection against NE-induced spasm. In addition, nifedipine prevents NE-induced
spasm only when given intraluminally. Same study has also shown that verapamil is the most
potent and versatile vasodilator with effective graft protection of up to 2 hr whether applied
externally or internally and is the preferred agent for protecting against GEA spasm [136].
During intraoperative preparation of the GEA graft, GTN and papaverine to a lesser extent,
used as topical vasodilators, appear to be more efficient in external application to increase the
free flow of the GEA [81]. GV solution has been suggested to be suitable to treat spasm of GEA
[137] GTN has a more rapid onset and verapamil has a longer action than papaverine [11].
That should prevent spasm of conduit in the early postoperative hours [137].
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4.3. Inferior epigastric artery
It has been demonstrated that there is no difference between the IEA and the IMA for some
vasoconstrictors, such as ET, NE, K+, and U46619 [48] However, a previous study showed that
IEA contracted less in response to histamine, but relaxed more in response to endothelium-
dependent vasodilators, compared with the IMA [138]. Different contractile responses to
TXA2 and NE between the IEA and the IMA have also been reported [139]. In general, it has
been argued that the contractile response of the IEA is basically similar to that of the IMA [11].
It has been demonstrated that endothelium dependent relaxation is reduced in the IEA
compared with the IMA [140]. Another report has shown that the non–receptor-mediated
endothelium dependent relaxation (induced by calcium ionophore A23187) in the IEA is less
than in the IMA, although the receptor-mediated endothelium-dependent relaxation induced
by acetylcholine is similar [48]. This decreased endothelium-dependent relaxation may be an
early sign of arteriosclerosis in the IEA [48], since non– receptor-mediated endothelium-
dependent relaxation is impaired.
5. Conclusion
The problem of grafts spasm has become more obvious with the increasing use of new arterial
grafts. Arterial spasm is a multifactor phenomenon modulated by different mechanism, such
as drugs, temperature, endogenous catecholamine, and mechanical stimuli (surgical trauma),
which is the most common cause. Surgical trauma can usually be minimized by harvesting the
artery as a pedicle rather than skeletonizing it by careful surgical technique.
Antispastic management is an important part of technical considerations during CABG
surgery. There is extensive evidence that the use of appropriate vasodilators during CABG
surgery can facilitate the operative procedure as well as improve graft flow and reduce
structural damage to the graft conduit. Spasm of arterial graft conduits is best managed by
prevention rather than treatment after it has occurred. There are many dilators of arterial grafts
that vary in potency, rapidity of onset, and duration of action as shown in organ bath studies.
Using these findings to make a rational choice of type of dilator and optimal concentration for
clinical use requires an understanding of the reactivity of that particular type of graft to
vasoconstrictor and vasodilator agents. In addition, clinical choice of grafts must be based on
consideration of many additional factors, including the systemic effects of the agent if it enters
the circulation, the effect of the agent and its vehicle on the endothelium, convenience of
preparation, and cost.
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